Winston Pharmaceuticals, Inc.’s (WPHM.OB) Lead Compound Granted Orphan Drug Designation
Winston Pharmaceuticals, Inc. announced that it has been granted orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead compound, Civamide, a novel TRPV-1 receptor modulator being developed as a dermal patch for the treatment of post-herpetic neuralgia. The company recently released results of a Phase I study demonstrating the patch's ease of use with repeated 24-hour applications. The lack of systemic absorption of Civamide from the patch should permit its use as either a monotherapy or as adjunctive therapy in combination with systemic medications used to treat post-herpetic neuralgia such as Cymbalta(R) (Duloxetine) and Lyrica(R)…